Nimbus Discovery Unveils First Of Its Kind Drug Discovery Paradigm; Announces Seed Round Co-Led By Bill Gates

Published: Mar 10, 2011

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Discovery LLC, a biopharmaceutical company using state-of the-art computational technology to discover novel medicines against exciting but difficult-to-drug disease targets, today announced an extension of its seed round with an investment by Bill Gates and Dr. Richard Friesner, the co-founder of Schrödinger and Professor of Chemistry at Columbia University. Atlas Venture, the founding investor, also participated.

Back to news